Table 3.

Univariate predictors of survival and being alive and engrafted for the period 1994–1999 and 1999–2004

	(A&E): 1994–1998					(A&E): 1999–2004
	n	(%)	OR	95% CI	P-value	n	(%)	OR	95% CI	P-value
Overall	51	57				95	56
HLA disparity
Matched	36	67	1			60	62	1
Mismatched	15	33	0.25	0.07–0.90	0.033	35	46	0.53	0.22–1.22	0.13
Conditioning a
Bu/Cy	30	54	1			36	53	1
Bu/Cyhi	17	59	1.25	0.38–4.16	0.72	13	77	2.98	0.70–12.67	0.14
Bu target	4	75	2.63	0.24–28.20	0.43	11	91	8.95	1.04–77.37	0.046
Flud-based MA	—	—	—	—	—	17	77	2.15	0.63–7.36	0.22
RIC	—	—	—	—	—	18	11	0.11	0.02–0.56	0.008
TCD b
No	47	62	—	—	—	61	65	1
Yes	4	0	—	—	—	24	29	0.22	0.08–0.61	0.004
Donor
Family	21	70	1			29	48	1
Unrelated	30	46	0.38	0.12–1.21	0.10	66	59	1.55	0.65–3.73	0.33
Source
BM	47	62	1			56	50	1
PBSC	1	0	—	—	—	19	52	1.11	0.39–3.15	0.84
CB	3	0	—	—	—	20	75	3.00	0.96–9.37	0.059 c

Abbreviations: A&E=alive and engrafted; BM=bone marrow; CB=cord blood; CI=confidence interval; ERT=enzyme replacement therapy; Flud-MA=fludarabine-based myeloablative; HLA=human leucocyte antigen; OR=odds ratios; PBSC=peripheral blood stem cell; RIC=reduced-intensity conditioning; TCD=T-cell depletion.

Multivariate analysis resulted in a similar outcome (predictors of being A&E) to that found in the overall group.

^aBusulfan was given in the regular myeloablative doses (16 or 20 mg/kg) p.o., unless otherwise indicated. Groups were subdivided as described in Table 1.

^bCD3+ ranging from <5 × 10⁴/kg to 10⁷/kg.

^cIn the multivariate analysis P=0.20.

P-values <0.1 were selected for multivariate analysis. Bold and italic indicates the P-value, bold alone for the OR.